20:29 , Apr 29, 2019 |  BC Extra  |  Company News

With Immunomedics ADC deal, Everest bolsters cancer pipeline

Undeterred by a complete response letter issued by FDA in January for Immunomedics' sacituzumab govitecan, Everest obtained the therapy's rights in several Asian territories, making the antibody-drug conjugate Everest's most advanced oncology asset thus far....
17:25 , Jun 29, 2018 |  BC Week In Review  |  Company News

China's Everest gets rights to Novartis' FGFR4 inhibitor

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) gained an exclusive, worldwide license to FGF401 from Novartis AG (NYSE:NVS; SIX:NOVN). The deal marks the second in-licensing of a fibroblast growth factor (FGF) receptor 4 (FGFR4; CD334) inhibitor...
00:23 , Jun 26, 2018 |  BC Extra  |  Company News

China's Everest gets rights to Novartis' FGFR4 inhibitor

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) gained an exclusive, worldwide license to FGF401 from Novartis AG (NYSE:NVS; SIX:NOVN) on Monday. The deal marks the second in-licensing of a fibroblast growth factor (FGF) receptor 4 (FGFR4;...